TSO3 deal with Getinge may set stage for takeout, says Laurentian

TS03's low-temperature 125 litre STERIZONE® sterilizer is designed for terminal sterilization of heat and moisture sensitive medical devices.

A deal that will see Getinge become the exclusive agent for TSO3’s (TSX:TOS) core product heightens the possibility that the former may buy the latter, says Laurentian Bank Securities analyst Nick Agostino. Yesterday, TSO3 announced it had granted Getinge Infection Control AB the exclusive global rights to distribute its Sterizone VP4 sterilizer for (U.S.) $7.5-million, […]

NYX Gaming is just getting started, says Cantor Fitzgerald

NYX Gaming CEO Matt Davey.

The value drivers are just beginning to align for NYX Gaming (TSXV:NYX) and investors should soon see another gear for the acquisitive company, says Cantor Fitzgerald Canada analyst Ralph Garcea. Yesterday, NYX reported its Q3, 2015 results. The company lost $6.49-million on revenue of $13.3-million, a 111.6 per cent bump over last year’s third quarter […]

Syncordia is a speculative buy, says Mackie Research Capital


A second quarter that was essentially in-line with his expectations hasn’t dampened Mackie Research Capital analyst Nikhil Thadani’s bullish stance on Syncordia Technologies (TSXV:SYN). Yesterday, Syncordia reported its Q2, 2015 results. The company lost (U.S.) $137,607 on revenue of $3.89-million. “We are very pleased with the organic growth and better customer accountability and focus at […]

Cantor Fitzgerald maintains “Buy” on Pivot Technology after strong Q3


A better than expected third quarter has Cantor Fitzgerald Canada analyst Ralph Garcea feeling bullish about Pivot Technology Solutions (TSXV:PTG). Yesterday, Pivot Technology reported its Q3, 2015 results. The company lost (U.S.) $2.6-million on revenue of $414.5-million, a topline that was up 15.2 per cent over 2014’s third quarter. “While we experienced solid revenue growth […]

Photon Control is still undervalued, says Euro Pacific


Euro Pacific Canada analyst Amr Ezzat says Photon Control’s (TSXV:PHO) third quarter results highlight the resilience of the company’s business model against the backdrop of a weak semiconductor market cycle. Yesterday, Photon Control reported its Q3, 2015 results. The company earned $2.64-million on sales of $6-million, an 18 per cent bump over the $5.1-million topline […]

Apivio Systems third quarter results get thumbs up at Haywood

Apivio CEO Rob Bakshi.

Apivio’s (TSX:APV) third quarter results were “exceptionally strong” says Haywood analyst Pardeep Sangha. This morning, Apivio reported its third quarter, 2015 results. The company earned $516,529 on sales of $16.86-million, up 52% from the $11.07-million topline the company posted in the same period a year prior. “We are pleased with the unexpectedly high performance of […]

AcuityAds is still undervalued, says Paradigm


A better than expected third quarter has Paradigm Capital analyst Spencer Churchill feeling bullish about AcuityAds (TSXV:AT). On Wednesday, AcuityAds reported its Q3, 2015 results. The company lost $586,337 on revenue of $5.47-million, a topline that was up 66 per cent over the same period last year. “We had a record quarter that saw our […]

Telesta Therapeutics gets price target slashed at Euro Pacific


Telesta Therapeutics (TSX:TST) received news today from the FDA that was a clear negative even if the reasoning behind it may be puzzling, says Euro Pacific Canada analyst Doug Loe. This morning, Telesta announced a negative result in its biologics licence application (BLA) for MCNA. The FDA voted 18 “no’s” to six “yes’s” to the […]

ProMetic’s deal with ProThera gets thumbs up at Paradigm

Prometic Life Sciences CEO Pierre Laurin.

Paradigm Capital analyst Christopher Lam likes the partnership ProMetic Life Sciences (TSX:PLI) signed today and expects similar deals will happen in the future. This morning, ProMetic announced it had entered into a strategic partnership with ProThera Biologics Inc. for the development and commercialization of human plasma-derived interalpha inhibitor proteins. “We are very pleased to be […]